129-17-9
CAS 129-17-9
129-17-9 (CAS 129-17-9) is a pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 25060.130303030306 nM | 33 | - |
| - | AC50 | 6090 nM | 2 | - |
| - | IC50 | 17707 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 129-17-9 used for in pharmaceutical contexts?
129-17-9 (CAS 129-17-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 129-17-9?
No adverse-event association or SIDER side-effect rows are rendered for 129-17-9 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 129-17-9 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for CI 42045 (Acid Blue 1 / D&C Blue No. 4) with EU status "restricted".
What clinical phase is 129-17-9 in?
No phase 1-4 clinical development badge is rendered for 129-17-9 because the matched compound identifier rows do not contain a max-phase value.